Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.
Status:
Completed
Trial end date:
2021-03-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of the metformin glycinate
and standard treatment of the hospital in hospitalized patients with Severe Acute Respiratory
Syndrome secondary to SARS-CoV2.